We are live on ! Find out more
ALLO icon

Allogene Therapeutics
ALLO

154 hedge funds and large institutions have $413M invested in Allogene Therapeutics in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 67 increasing their positions, 37 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

81% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 37

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

10% less funds holding

Funds holding: 171 → 154 (-17)

13.74% less ownership

Funds ownership: 91.47% → 77.73% (-14%)

38% less capital invested

Capital invested by funds: $663M → $413M (-$250M)

55% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 29

58% less call options, than puts

Call options by funds: $195K | Put options by funds: $469K

Holders
154
Holders Change
-17
Holders Change %
-9.94%
% of All Funds
2.44%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
13
Increased
67
Reduced
37
Closed
29
Calls
$195K
Puts
$469K
Net Calls
-$274K
Net Calls Change
-$97K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$13.5M
2
JP Morgan Chase
JP Morgan Chase
New York
+$3.4M
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$2.39M
4
BlackRock
BlackRock
New York
+$1.96M
5
CANY
Caxton Associates (New York)
New York
+$1.8M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$12.8M
2
BBA
Baker Bros. Advisors
New York
-$7.84M
3
Cerity Partners
Cerity Partners
New York
-$2.97M
4
Two Sigma Investments
Two Sigma Investments
New York
-$2.86M
5
Citadel Advisors
Citadel Advisors
Florida
-$2.74M
Name Holding Trade Value Shares
Change 		Change in
Stake
PFBT
151
Parkside Financial Bank & Trust
Missouri
$505 – – –
Toronto Dominion Bank
152
Toronto Dominion Bank
Ontario, Canada
$86 – – –
BBA
153
Baker Bros. Advisors
New York
– -$7.84M -1,576,901 Closed
Cerity Partners
154
Cerity Partners
New York
– -$2.97M -598,100 Closed
IHAM
155
Integral Health Asset Management
New York
– -$2.05M -412,000 Closed
Thrivent Financial for Lutherans
156
Thrivent Financial for Lutherans
Minnesota
– -$644K -129,535 Closed
Walleye Capital
157
Walleye Capital
New York
– -$572K -115,032 Closed
SSA
158
Schonfeld Strategic Advisors
New York
– -$508K -102,285 Closed
EGM
159
Engineers Gate Manager
New York
– -$476K -95,746 Closed
GCM
160
Graham Capital Management
Connecticut
– -$310K -62,431 Closed
PMEF
161
Point72 Middle East FZE
United Arab Emirates
– -$270K -54,242 Closed
Mackenzie Financial
162
Mackenzie Financial
Ontario, Canada
– -$264K -53,192 Closed
TI
163
Trexquant Investment
Connecticut
– -$250K -50,336 Closed
Allianz Asset Management
164
Allianz Asset Management
Germany
– -$211K -42,400 Closed
Los Angeles Capital Management
165
Los Angeles Capital Management
California
– -$205K -41,227 Closed
Prudential Financial
166
Prudential Financial
New Jersey
– -$168K -33,890 Closed
DTL
167
Dynamic Technology Lab
Singapore
– -$164K -33,095 Closed
Axa
168
Axa
France
– -$141K -28,300 Closed
NRD
169
Nebula Research & Development
New York
– -$134K -26,900 Closed
CA
170
Calton & Associates
Florida
– -$114K -22,907 Closed
Capstone Investment Advisors
171
Capstone Investment Advisors
New York
– -$107K -21,438 Closed
CCIA
172
Campbell & Co Investment Adviser
Maryland
– -$94.2K -18,952 Closed
I
173
InceptionR
California
– -$80.5K -16,203 Closed
OGF
174
Orin Green Financial
California
– -$79.5K -15,990 Closed
DU
175
Delphia (USA)
Ontario, Canada
– -$68.2K -13,714 Closed
4 5 6
7
8

ALLO Hedge Fund Activity: Q3 2023 in Review

154 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q3 2023, worth a combined $413M — down 38% from $663M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of ALLO and 13 opened new positions — a net loss of 16 holders — while 37 trimmed existing stakes and 67 added.

The largest buyer was Vanguard Group, adding an estimated $13.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $12.8M.

  • 154 institutional investors held Allogene Therapeutics (ALLO) as of Q3 2023, down from 171 in Q2 2023.
  • Funds reported $413M of Allogene Therapeutics stock for Q3 2023, down 38% quarter-over-quarter.
  • 13 funds opened new Allogene Therapeutics positions in Q3 2023 and 29 closed out, a net change of -16 holders.
  • The largest Allogene Therapeutics buyer in Q3 2023 was Vanguard Group, an estimated $13.5M added.
  • The largest Allogene Therapeutics seller in Q3 2023 was T. Rowe Price Associates, an estimated $12.8M sold.

Based on aggregated 13F filings for Q3 2023.